1. What conditions has Maitake Mushrooms been studied for?

• Cancer (primarily as an immunomodulatory/anticancer agent)

  • Breast cancer cell models (MCF-7) with maitake “D-Fraction” (in vitro gene-expression and apoptosis-related work).

  • Solid tumor cell viability assays using molecular-weight fractions of maitake β-glucans (in vitro cytotoxicity).

  • More broadly, maitake is listed among supplements with “best suggestions of benefit” for patients undergoing cancer therapy in an integrative oncology context (clinical guidance-oriented review, not a single trial).

• Liver injury / hepatitis (toxic/drug-induced)

  • Acetaminophen (paracetamol)-induced hepatitis in rats using a thick maitake extract (preclinical hepatoprotection study).

• Dyslipidemia / cholesterol biosynthesis (dietary biomarker and mechanistic angle)

  • Ergosterol from mushrooms reported to inhibit cholesterol biosynthesis; a human study measured serum ergosterol after consuming maitake mushroom bread to confirm ingestion (biomarker/ingestion confirmation rather than a treatment trial).

• Gut microbiota / probiotic-food interactions (functional ingredient research)

  • Maitake listed among ingredients with demonstrated health benefits “through gut microbiota,” and studied for effects on yogurt starter/probiotic characteristics (food science/probiotic functionality focus).

• Nutrition/food fortification

  • Semolina pasta enriched with maitake powder assessed for nutrition and sensory/physical properties (food formulation; not a disease-treatment study).

2. Does it work in treating those conditions? Summarize the evidence.

• Cancer: Evidence in these studies is largely preclinical (cell studies) plus a clinical-practice-oriented review suggesting potential benefit.

  • In MCF-7 breast cancer cells, maitake D-Fraction altered expression of thousands of genes (4068 total; 2420 up, 1648 down) and was interpreted as affecting pathways related to apoptosis, growth inhibition, cell-cycle arrest, migration/metastasis, and multidrug sensitivity (in vitro; mechanistic hypothesis-generating).

  • Fractionated β-glucan extracts showed that certain molecular-weight fractions (including >100 kDa and 5–10 kDa) reduced viability in two solid tumor cell types (in vitro cytotoxicity; does not establish clinical efficacy).

  • An integrative oncology committee document includes maitake among supplements with “best suggestions of benefit” for patients in cancer therapy and emphasizes discussing evidence, uncertainty, adverse effects, and interactions—this supports that maitake is considered plausible/commonly used, but the study does not provide specific clinical outcomes or trial results.

  • Bottom line: These studies support biological plausibility and in vitro activity, but they do not establish that maitake treats cancer in humans.

• Acetaminophen-induced liver injury: In rats, maitake thick extract (150 mg/kg) given around the time of acetaminophen exposure improved liver injury markers (ALT, AST, GGTP, alkaline phosphatase, thymol test) and histology, suggesting hepatoprotective/cytoprotective/antioxidant effects in this model.

  • Bottom line: Promising animal evidence for toxin-induced hepatitis; human efficacy is not established in these studies.

• Dyslipidemia/cholesterol: The study describes ergosterol as an inhibitor of cholesterol biosynthesis and reports measuring serum ergosterol after maitake bread consumption to confirm ingestion.

  • Bottom line: This supports feasibility of tracking intake and a mechanistic rationale (ergosterol), but does not demonstrate cholesterol lowering or dyslipidemia treatment in the described abstract.

• Gut microbiota/probiotic effects: Maitake is included among ingredients thought to have benefits via gut microbiota, and the study aim is to test impacts on probiotic characteristics/tolerance/viability.

  • Bottom line: This is supportive of a research direction (functional food/probiotic performance), but does not establish clinical treatment effects for a specific condition.

3. What health benefits does it have?

• Immune modulation / immunostimulation (preclinical/biological rationale): The cancer-focused abstract states maitake D-Fraction is known to stimulate the immune system and activate macrophages, T-cells, and natural killer cells (general mechanistic claim; not a clinical endpoint in the study).

• Potential anticancer activity (preclinical):

  • D-Fraction altered gene expression in breast cancer cells in ways interpreted as supporting apoptosis and suppression of tumor phenotype (in vitro).

  • Specific β-glucan molecular-weight fractions inhibited tumor cell viability in vitro.

• Hepatoprotective effects (animal model): In acetaminophen-induced hepatitis in rats, maitake thick extract improved liver enzymes and histology, consistent with hepato-, cyto-protective and antioxidative properties.

• Possible cholesterol-biosynthesis inhibition via ergosterol (mechanistic): Ergosterol present in mushrooms is described as inhibiting cholesterol biosynthesis; serum ergosterol can serve as a biomarker of maitake intake in a bread intervention setting.

• Nutritional/functional food benefits: Adding dried maitake powder to pasta increased nutritional value (notably ash, protein, and dietary fiber) in the enriched pasta variants.

• Potential gut-microbiota-related functional benefits: Maitake is grouped with ingredients described as having health benefits through gut microbiota, and is being studied for effects on probiotic characteristics in fermented foods.

4. Does it have any downsides or side effects?

• Not well characterized in these studies: The studies reviewed here do not give specific adverse event rates in humans for maitake.

• Potential for drug/supplement interactions (general caution in oncology): The integrative oncology abstract emphasizes that supplements (including maitake) should be discussed with clinicians because adverse effects and interactions with medications are relevant, and non-disclosure is common. However, it does not list specific maitake interactions in the excerpt provided.

• Food formulation tolerability/quality considerations (not a medical side effect): In mushroom-enriched pasta research, some mushroom additions increased cooking loss and changed physical properties; this is a product-quality downside rather than a health harm.

• Evidence limitation: Because much of the efficacy evidence cited here is in vitro or animal-based, safety conclusions for clinical populations (e.g., people on chemotherapy, immunotherapy, anticoagulants, or with autoimmune disease) cannot be reliably drawn from these studies alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (i.e., no data linking maitake response or toxicity to specific human genetic variants).

• What is reported instead: An in vitro microarray study shows maitake D-Fraction changes expression of many genes in MCF-7 breast cancer cells (e.g., IGFBP-7, ITGA2, ICAM3, SOD2, CAV-1, Cul-3, NRF2, Cyclin E, ST7, SPARC). This is gene-expression modulation in a cell line, not evidence that people with particular inherited variants benefit more or are at higher risk.

• Practical implication: At present, based on these studies, there is no evidence-based way to tailor maitake use according to genotype.

Summary of Research on Maitake Mushroom

Clinical Trial on Immune Effects in Breast Cancer Patients

A clinical trial investigated the immune effects of Maitake mushroom polysaccharide extract in postmenopausal breast cancer patients. The trial included 34 women who were given the extract orally, with blood samples analyzed for immune response. No major toxicity was found, but two patients experienced mild side effects. The extract showed significant, complex impacts on immune function, with both stimulating and inhibitory effects depending on the dose.

Maitake D-Fraction and Cancer Treatment

The potential of Maitake D-Fraction (PDF), particularly its immunomodulatory and antitumor effects, was discussed. PDF, combined with vitamin C, has shown synergistic effects in vitro, indicating a possible enhancement of cancer therapies. The combination is also being considered for practical therapeutic approaches.

Maitake Mushroom and Neurodegenerative Diseases

Grifola frondosa, known as Maitake mushroom, has been reviewed for its neuroprotective effects against diseases like Alzheimer's and Parkinson's. The mushroom's compounds provide antioxidant and anti-inflammatory benefits, stimulate neuronal growth, and counteract β-amyloid activity.

Anti-Cancer Properties and Breast Cancer

Edible/medicinal mushrooms, including Maitake, have been traditionally used for health benefits and are now recognized for their antineoplastic activity against breast cancer. The review covers the bioactive compounds in these mushrooms and their mechanisms of action.

Meta-Analysis of Maitake Polysaccharide

A meta-analysis of preclinical studies on Grifola frondosa polysaccharide (GFP) showed significant tumor growth inhibition, tumor remission, and immune function enhancement. The study supports GFP's potential as a tumor treatment and suggests further clinical trials.

Impact of Maitake D-Fraction on Immune Response in Cancer Patients

A study evaluated Maitake D-Fraction's effects on natural killer (NK) cell activation in cancer patients. The results indicated increased NK cell activity and inhibited metastatic progression, suggesting the immunotherapy's potential in cancer progression inhibition.

Maitake D-Fraction in Advanced Laryngeal and Pharyngeal Cancers

In a clinical trial, patients with advanced laryngeal and pharyngeal cancers undergoing chemoradiotherapy received Maitake D-Fraction. The group taking the supplement had fewer severe adverse events, improved quality of life, and better recovery compared to the placebo group.

References:

1. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects
2. Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy
3. Maitake Medicinal Mushroom, Grifola frondosa (Agaricomycetes), and Its Neurotrophic Properties: A Mini-Review
4. Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer
5. Antitumor activities of Grifola frondosa (Maitake) polysaccharide: A meta-analysis based on preclinical evidence and quality assessment
6. Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients
7. Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: A randomized clinical trial
8. Unveiling the full spectrum of maitake mushrooms: A comprehensive review of their medicinal, therapeutic, nutraceutical, and cosmetic potential.
   Emma Camilleri, Renald Blundell, Bikash Baral, Tomasz M Karpiński, Edlira Aruci, Omar M Atrooz (2024) - Heliyon
9. Integrating dietary supplements into cancer care.
   Moshe Frenkel, Donald I Abrams, Elena J Ladas, Gary Deng, Mary Hardy, Jillian L Capodice, Mary F Winegardner, J K Gubili, K Simon Yeung, Heidi Kussmann, Keith I Block (2013) - Integrative cancer therapies
10. Attributes of Culture Bacteria as Influenced by Ingredients That Help Treat Leaky Gut.
    Ricardo S Aleman, David Paz, Roberto Cedillos, Miguel Tabora, Douglas W Olson, Kayanush Aryana (2023) - Microorganisms
11. Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells.
    Eliana Noelia Alonso, Manuela Orozco, Alvaro Eloy Nieto, Gabriela Andrea Balogh (2013) - Journal of medicinal food
12. The effect of the addition of various species of mushrooms on the physicochemical and sensory properties of semolina pasta.
    Magdalena Szydłowska-Tutaj, Urszula Złotek, Agnieszka Wójtowicz, Maciej Combrzyński (2022) - Food & function
13. Application of the thick extract from Maitake mushrooms for correction of metabolic disorders under the paracetamol hepatitis in rats.
    Iryna Herasymets, Liudmyla Fira, Ihor Medvid (2021) - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
14. Characterization of Cross-Flow Ultrafiltration Fractions from Maitake Medicinal Mushroom, Grifoia frondosa (Agaricomycetes), Reveals Distinct Cytotoxicity in Tumor Cells.
    Miriam Sari, Reinhard Hambitzer, Jan I Lelley, Katharina Toepler, Nicole Teusch, Anna Nickisch-Hartfiel (2016) - International journal of medicinal mushrooms
15. Application of ergosterol as a maitake mushroom intake biomarker.
    Naoko Kuwabara, Eri M Jogi, Masaharu Kato, Yuki Masuda, Morichika Konishi, Kenji Yamasaki, Shuzo Ohata, Setsushi Kato, Michio Hashimoto, Shinji Sato, Saori Nakagawa (2025) - Annals of clinical biochemistry

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!